Multiple Myeloma News & Features
Patients with multiple myeloma may be vulnerable to financial toxicity, even those with health insurance and those who make more than $100,000 a year, due to the higher use of novel therapeutics and extended duration of myeloma treatment.
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
War veterans exposed to Agent Orange, an herbicidal agent used for warfare, have more than a 2-fold increased risk for monoclonal gammopathy of undetermined significance.
Among patients with multiple myeloma, high compliance with exercise was associated with improvements in fatigue.
A genetic variation in the FOPNL gene can increase mortality for patients with multiple myeloma.
Multiple Myeloma Clinical Trials
- Risk of Some Cancers Modestly Increased in Persons Who Had Herpes Zoster
- Blood Test Indicates Breast Cancer Tumors Developed Resistance to Hormone Treatment
- Breakthrough Advance Announced in International Blood Cancer Drug Trial
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Survival for Follicular, Diffuse Large B-cell Lymphomas Improving in Europe
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Navigation Program Tackles Cancer Care on Two Fronts
- Liquid Biopsy of Cerebrospinal Fluid More Effective in Managing Brain Tumors
- Nivolumab Indications Extended to Include Advanced Renal Cell Carcinoma
- S-1 as First-line Chemo for HER2- Metastatic Breast Cancer
- Nanoliposomal Irinotecan Extends Survival in Metastatic Pancreatic Cancer
- Blood Test Identifies Mutations Behind Drug Resistance in Patients Taking Antiandrogen for Prostate Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|